Amgen Shares Surge on Strong Earnings and Cardiovascular Drug Breakthrough

Biotechnology leader Amgen is experiencing a significant rally, propelled by a powerful combination of exceptional financial performance and a major clinical achievement. The company’s latest quarterly report shattered forecasts, while groundbreaking trial data for its heart medication Repatha has generated substantial market optimism.

Robust Quarterly Earnings Exceed Forecasts

Amgen delivered a standout financial performance for the third quarter of 2025. The company reported earnings per share of $5.64, decisively beating analyst estimates by a notable 63 cents. Revenue growth was equally impressive, climbing 12.4% year-over-year to reach $9.56 billion. These results not only demonstrate the firm’s operational strength but also highlight its exceptional profitability, evidenced by a net margin approaching 19%.

Management’s confidence in the company’s trajectory is reflected in its revised annual guidance. Amgen has raised its full-year earnings per share forecast to a range between $20.60 and $21.40, sending a positive signal to the investment community.

Cardiovascular Drug Trial Delivers Landmark Results

Beyond the financial headlines, a medical breakthrough is providing additional momentum. The Phase 3 VESALIUS-CV study for the cholesterol-lowering drug Repatha achieved spectacular results, showing a 25% reduction in major cardiovascular events among high-risk patients.

Should investors sell immediately? Or is it worth buying Amgen?

This outcome positions Repatha as the first medication in its class to demonstrate compelling efficacy in both primary and secondary prevention. This therapeutic advancement could potentially unlock access to new multi-billion dollar markets for the blockbuster treatment.

Market Analysts Maintain Cautious Stance Despite Rally

Despite these compelling developments, many market researchers are exhibiting surprising restraint. While some firms like Piper Sandler and DZ Bank have set bullish price targets of $342 and $364 respectively, the overall consensus rating remains “Hold.” The average price target sits around $310, which is considerably below recent peak valuations.

Institutional investor activity also reveals a divided picture. Several funds have scaled back their holdings, while Vise Technologies Inc. established a new position with a $4.3 million investment.

The central question remains whether Amgen can maintain its upward trajectory in the face of market skepticism. The company’s solid fundamentals and recent medical achievement present a strong case, yet the gap between current share performance and analyst targets indicates that further market persuasion may be required.